T cells in health and disease

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: June 19, 2023

T cells are crucial for immune functions to maintain health and prevent disease. cell development occurs in a stepwise process the thymus mainly generates CD4

Language: Английский

---

Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses

Cell, Journal Year: 2021, Volume and Issue: 184(25), P. 6101 - 6118.e13

Published: Nov. 30, 2021

Language: Английский

---

The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes

Cell, Journal Year: 2022, Volume and Issue: 185(22), P. 4049 - 4066.e25

Published: Oct. 1, 2022

Language: Английский

---

Dynamics and specificities of T cells in cancer immunotherapy

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(5), P. 295 - 316

Published: April 12, 2023

Language: Английский

---

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

Cell, Journal Year: 2023, Volume and Issue: 186(6), P. 1127 - 1143.e18

Published: March 1, 2023

CD8

Language: Английский

---

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

Immunity, Journal Year: 2022, Volume and Issue: 56(1), P. 107 - 124.e5

Published: Dec. 28, 2022

Language: Английский

---

CD8+ T cells in the cancer-immunity cycle

Immunity, Journal Year: 2023, Volume and Issue: 56(10), P. 2231 - 2253

Published: Oct. 1, 2023

Language: Английский

---

Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade

Nature Cancer, Journal Year: 2022, Volume and Issue: 3(9), P. 1123 - 1136

Published: Sept. 22, 2022

Language: Английский

---

‘Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses

Nature Immunology, Journal Year: 2022, Volume and Issue: 23(6), P. 836 - 847

Published: May 27, 2022

Language: Английский

---

Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

Immune Network, Journal Year: 2022, Volume and Issue: 22(1)

Published: Jan. 1, 2022

Targeting immune evasion via checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved 2011 for of metastatic melanoma, eight inhibitors (ICIs) centered on PD-1 pathway blockade are and currently administered to treat 18 different types cancers. The part review focuses history discovery preclinical experiments that demonstrated possibility anti-CTLA-4 anti-PD-1 as anti-cancer therapeutics. approval process clinical trials utility ICIs described, specifically focusing non-small cell lung cancer (NSCLC), which immunotherapies most actively applied. Additionally, this covers combination therapy novel under investigation NSCLC. Although now key pivotal option settings, they show inconsistent therapeutic efficacy limited responsiveness. Thus, newly proposed action mechanism overcome limitations a near future also discussed.

Language: Английский

---